KALA · XBRL financial data
KALA BIO financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (KALA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 18,352 | — | — | — | — | — |
| Selling, general and administrative | 81,068 | 105,061 | 65,035 | 20,567 | — | — |
| General and administrative | — | — | — | 20,567 | 18,340 | 23,629 |
| Total operating expenses | 102,593 | 141,485 | 85,598 | 39,663 | 40,983 | 39,161 |
| Other operating income (expense) | (8,096) | (12,360) | — | — | — | — |
| Operating income (loss) | (96,231) | (130,245) | (81,706) | (39,663) | (40,983) | (39,161) |
| Interest income | 493 | 104 | 664 | 2,711 | 2,056 | 1,140 |
| Interest expense | 8,589 | 8,380 | 7,266 | 5,814 | 5,783 | 3,276 |
| Other income (expense) | — | — | (926) | (4,258) | — | 5,147 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (104,327) | (142,605) | (44,822) | (42,199) | (38,511) | (26,980) |
| Earnings per share, basic‡ USD per share | (4,975.00) | (5,475.00) | (1,474.00) | (867.50) | (507.50) | (165.50) |
| Earnings per share, diluted‡ USD per share | (4,975.00) | (5,475.00) | (1,474.00) | (867.50) | (507.50) | (165.50) |
| Weighted average shares, basic‡ thousands of shares | 21 | 26 | 30 | 49 | 76 | 163 |
| Weighted average shares, diluted‡ thousands of shares | 21 | 26 | 30 | 49 | 76 | 163 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (May 2026); filings made before it reported them unadjusted.
- † Share count changed about 144x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (KALA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 77,264 | 92,136 | 70,495 | 50,895 | 51,181 | 7,557 |
| Short-term investments | 76,276 | — | — | — | — | — |
| Accounts receivable | 9,604 | 15,345 | 195 | — | — | — |
| Inventory | 5,229 | 8,639 | — | — | — | — |
| Prepaid and other current assets | 3,006 | 6,204 | 7,657 | 1,975 | 1,616 | 1,933 |
| Total current assets | 171,379 | 124,366 | 85,942 | 52,870 | 52,797 | 9,490 |
| Property and equipment, net | 3,166 | 2,722 | 400 | 753 | 749 | — |
| Right-of-use asset | 27,853 | 1,299 | 16 | 2,025 | 1,691 | — |
| Total assets | 221,606 | 139,427 | 86,820 | 55,949 | 55,483 | 9,490 |
| Accounts payable | 1,724 | 4,899 | 2,832 | 919 | 628 | 986 |
| Accrued liabilities | 18,971 | 20,986 | 8,910 | 6,018 | — | — |
| Current portion of long-term debt | — | — | 5,000 | — | 10,336 | — |
| Total current liabilities | 22,225 | 37,422 | 25,685 | 8,346 | 16,956 | 2,494 |
| Long-term debt | 72,243 | 78,929 | 37,937 | 34,190 | 20,102 | — |
| Lease liability, non-current | — | 548 | — | 1,799 | 1,434 | — |
| Total liabilities | 121,611 | 122,623 | 67,846 | 48,445 | 43,151 | 2,494 |
| Accumulated deficit | (399,783) | (542,388) | (587,210) | (629,409) | (667,920) | (694,900) |
| Total stockholders' equity | 99,995 | 16,804 | 18,974 | 7,504 | 12,332 | 6,996 |
| Total liabilities and equity | 221,606 | 139,427 | 86,820 | 55,949 | 55,483 | 9,490 |
| Common shares outstanding (cover page)‡ thousands of shares | 25 | 29 | 41 | 56 | 129 | 18,590 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (May 2026); filings made before it reported them unadjusted.
- † Share count changed about 144x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (KALA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (104,327) | (142,605) | (44,822) | (42,199) | (38,511) | (26,980) |
| Stock-based compensation | 13,312 | 16,088 | 7,008 | 7,463 | 8,389 | 6,995 |
| Depreciation and amortization | 912 | 975 | 537 | 303 | 259 | 317 |
| Net cash from operating activities | (90,694) | (108,235) | (78,908) | (27,927) | (29,382) | (31,991) |
| Net cash from investing activities | (78,209) | 70,803 | 62,717 | (429) | (208) | (15) |
| Proceeds from issuing common stock | 158,557 | 41,232 | 1,036 | 18,536 | 3,394 | 9,134 |
| Proceeds from long-term debt | — | 77,782 | — | — | — | — |
| Net cash from financing activities | 160,628 | 42,554 | (7,942) | 8,506 | 29,876 | (11,618) |
| Net change in cash | (8,275) | 5,122 | (24,133) | (19,850) | 286 | (43,624) |
- † Share count changed about 144x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Kala Bio | 229 | not reported | (1,535)* | 19.3M | 4.7 quarters | 10-QJun 30, 2026 |
| Lexaria Bioscience | 3,500 | 0 | (1,635)* | 24.8M | 2.2 quarters | 10-QMay 31, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Dyadic International | 1,425 | 961 | (1,818)* | 36.4M | 1.7 quarters | 10-QJun 30, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Aytu Biopharma | 26,308 | 16,106* | 4,406* | 10.9M | — | 10-KJun 30, 2026 |
| Tenax Therapeutics | 118,000 | 0* | (14,150)* | 37.4M | 8.3 quarters | 10-QJun 30, 2026 |
| Nanoviricides | 2,794 | not reported | (2,122)* | 25.5M | 1.3 quarters | 10-KJun 30, 2026 |
| Lisata Therapeutics | 10,443 | 0 | (2,649)* | 9.0M | 3.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.